ALLOCETRA Trademark

Trademark Overview

On Tuesday, March 29, 2022, a trademark application was filed for ALLOCETRA with the United States Patent and Trademark Office. The USPTO has given the ALLOCETRA trademark a serial number of 97335677. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, September 24, 2024. This trademark is owned by Enlivex Therapeutics Ltd. The ALLOCETRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune and inflammatory diseases
allocetra

General Information

Serial Number97335677
Word MarkALLOCETRA
Filing DateTuesday, March 29, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, September 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 28, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune and inflammatory diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 4, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEnlivex Therapeutics Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressNes-Ziona 7403618
IL
Party NameEnlivex Therapeutics Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressNes-Ziona 7403618
IL

Trademark Events

Event DateEvent Description
Monday, April 4, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 1, 2022NEW APPLICATION ENTERED
Friday, January 13, 2023ASSIGNED TO EXAMINER
Friday, January 20, 2023EXAMINERS AMENDMENT -WRITTEN
Friday, January 20, 2023EXAMINERS AMENDMENT E-MAILED
Friday, January 20, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, January 20, 2023EXAMINER'S AMENDMENT ENTERED
Friday, January 20, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 25, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 10, 2023SOU EXTENSION 1 FILED
Tuesday, October 10, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 10, 2023SOU EXTENSION 1 GRANTED
Thursday, October 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 9, 2024SOU EXTENSION 2 FILED
Tuesday, September 24, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, September 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2024SOU EXTENSION 3 GRANTED
Tuesday, September 24, 2024SOU EXTENSION 3 FILED
Wednesday, April 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 9, 2024SOU EXTENSION 2 GRANTED
Tuesday, April 9, 2024SOU TEAS EXTENSION RECEIVED

Related Keywords

allocetra inflammatory diseases autoimmune treatment preparations pharmaceutical